Intestinal and Peripheral Fibrinogen-Like Protein 2 Expression in Inflammatory Bowel Disease

详细信息    查看全文

• 作者：Xiuli Dong (1)
  Xiaohua Ye (2)
  Xiangrong Chen (1)
  Tanzhou Chen (1)
  Saili Xie (1)
  Qinfan Li (1)
  Xiaoxiao Lin (1)
  Zhiming Huang (1)
  
• 关键词：Inflammatory bowel disease ; Fibrinogen ; like protein 2 ; Immunomodulation ; Ulcerative colitis ; Crohn’s disease ; Regulatory T cell
• 刊名：Digestive Diseases and Sciences
• 出版年：2014
• 出版时间：April 2014
• 年：2014
• 卷：59
• 期：4
• 页码：769-777
• 全文大小：8,181 KB
• 参考文献：1. Bernstein CN, Fried M, Krabshuis JH, et al. World Gastroenterology Organization practice guidelines for the diagnosis and management of IBD in 2010. / Inflamm Bowel Dis. 2010;16:112-24. CrossRef
  2. Khor B, Gardet A, Xavier RJ. Genetics and pathogenesis of inflammatory bowel disease. / Nature. 2011;474:307-17. CrossRef
  3. Nagalingam NA, Lynch SV. Role of the microbiota in inflammatory bowel diseases. / Inflamm Bowel Dis. 2012;18:968-84. CrossRef
  4. Maloy KJ, Powrie F. Intestinal homeostasis and its breakdown in inflammatory bowel disease. / Nature. 2011;474:298-06. CrossRef
  5. Rb S. Pathagenesis and immune mechanisms of chronic inflammatory bowel diseases. / Am J Gastroenterol. 1997;92:5S-1S.
  6. Matricon J. Immunopathogenesis of inflammatory bowel disease. / Med Sci. 2010;26:405-10.
  7. Scarpa M, Stylianou E. Epigenetics: concepts and relevance to IBD pathogenesis. / Inflamm Bowel Dis. 2012;18:1982-996. CrossRef
  8. Kaser A, Zeissig S, Blumberg RS. Inflammatory bowel disease. / Annu Rev Immunol. 2010;28:573-21. CrossRef
  9. Arseneau KO, Tamagawa H, Pizarro TT, Cominelli F. Innate and adaptive immune responses related to IBD pathogenesis. / Curr Gastroenterol Rep. 2007;9:508-12. CrossRef
  10. O’Garra A, Vieira P. Regulatory T cells and mechanisms of immune system control. / Nat Med. 2004;10:801-05. CrossRef
  11. Koyama THL, Haser WG, Tonegawa S, Saito H. Structure of a cytotoxic T-lymphocyte-specific gene shows a strong homology to fibrinogen beta and gamma chains. / Proc Natl Acad Sci USA. 1987;84:1609-613. CrossRef
  12. Ruegg C, Pytela R. Sequence of a human transcript expressed in T-lymphocytes and encoding a fibrinogen-like protein. / Gene. 1995;160:257-62. CrossRef
  13. Levy GA, Liu M, Ding J, et al. Molecular and functional analysis of the human prothrombinase gene (HFGL2) and its role in viral hepatitis. / Am J Pathol. 2000;156:1217-225. CrossRef
  14. Melnyk MC, Shalev I, Zhang J, et al. The prothrombinase activity of FGL2 contributes to the pathogenesis of experimental arthritis. / Scand J Rheumatol. 2011;40:269-78. CrossRef
  15. Fontenot JD, Rasmussen JP, Gavin MA, Rudensky AY. A function for interleukin 2 in Foxp3-expressing regulatory T cells. / Nat Immunol. 2005;6:1142-151. CrossRef
  16. Marazzi S, Blum S, Hartmann R, et al. Characterization of human fibroleukin, a fibrinogen-like protein secreted by T lymphocytes. / J Immunol. 1998;161:138-47.
  17. Chan CW, Kay LS, Khadaroo RG, et al. Soluble fibrinogen-like protein 2/fibroleukin exhibits immunosuppressive properties: suppressing T cell proliferation and inhibiting maturation of bone marrow-derived dendritic cells. / J Immunol. 2003;170:4036-044.
  18. Shalev I, Liu H, Koscik C, et al. Targeted deletion of fgl2 leads to impaired regulatory T cell activity and development of autoimmune glomerulonephritis. / J Immunol. 2008;180:249-60.
  19. Liu H, Shalev I, Manuel J, et al. The FGL2-FcgammaRIIB pathway: a novel mechanism leading to immunosuppression. / Eur J Immunol. 2008;38:3114-126. CrossRef
  20. Lennard-Jones JE. Classification of inflammatory bowel disease. / Scand J Gastroenterol. 1989;170:2-; discussion 16-9. CrossRef
  21. Truelove SC, Witts LJ. Cortisone in ulcerative colitis; final report on a therapeutic trial. / Br Med J. 1955;2:1041-048. CrossRef
  22. Vrij AA, Rijken J, Van Wersch JW, Stockbrugger RW. Platelet factor 4 and beta-thromboglobulin in inflammatory bowel disease and giant cell arteritis. / Eur J Clin Invest. 2000;30:188-94. CrossRef
  23. Best WR, Becktel JM, Singleton JW, Kern F Jr. Development of a Crohn’s disease activity index. National cooperative Crohn’s disease study. / Gastroenterology. 1976;70:439-44.
  24. Maul J, Loddenkemper C, Mundt P, et al. Peripheral and intestinal regulatory CD4+CD25 (high) T cells in inflammatory bowel disease. / Gastroenterology. 2005;128:1868-878. CrossRef
  25. Veltkamp C, Anstaett M, Wahl K, et al. Apoptosis of regulatory T lymphocytes is increased in chronic inflammatory bowel disease and reversed by anti-TNFalpha treatment. / Gut. 2011;60:1345-353. CrossRef
  26. Li Z, Arijs I, De Hertogh G, et al. Reciprocal changes of Foxp3 expression in blood and intestinal mucosa in IBD patients responding to infliximab. / Inflamm Bowel Dis. 2010;16:1299-310. CrossRef
  27. Kullberg MC, Hay V, Cheever AW, et al. TGF-beta1 production by CD4+CD25+ regulatory T cells is not essential for suppression of intestinal inflammation. / Eur J Immunol. 2005;35:2886-895. CrossRef
  28. Bachmann MF, Gallimore A, Jones E, Ecabert B, Acha-Orbea H, Kopf M. Normal pathogen-specific immune responses mounted by CTLA-4-deficient T cells: a paradigm reconsidered. / Eur J Immunol. 2001;31:450-58. CrossRef
  29. Yang XF. Factors regulating apoptosis and homeostasis of CD4+CD25 (high) FOXP3+ regulatory T cells are new therapeutic targets. / Front Biosci. 2008;13:1472-499. CrossRef
  30. Shalev I, Wong KM, Foerster K, et al. The novel CD4+CD25+ regulatory T cell effector molecule fibrinogen-like protein 2 contributes to the outcome of murine fulminant viral hepatitis. / Hepatology. 2009;49:387-97. CrossRef
  31. Foerster K, Helmy A, Zhu Y, et al. The novel immunoregulatory molecule FGL2: a potential biomarker for severity of chronic hepatitis C virus infection. / J Hepatol. 2010;53:608-15. CrossRef
  32. Chiquet-Ehrismann R, Hagios C, Matsumoto K. The tenascin gene family. / Perspect Dev Neurobiol. 1994;2:3-.
  33. Procopio WN, Pelavin PI, Lee WM, Yeilding NM. Yeilding, angiopoietin-1 and -2 coiled coil domains mediate distinct homo-oligomerization patterns, but fibrinogen-like domains mediate ligand activity. / J Biol Chem. 1999;274:30196-0201. CrossRef
  34. Herman AE, Freeman GJ, Mathis D, Benoist C. CD4+CD25+ T regulatory cells dependent on ICOS promote regulation of effector cells in the prediabetic lesion. / J Exp Med. 2004;199:1479-489. CrossRef
  35. Mendicino M, Liu M, Ghanekar A, et al. Targeted deletion of Fgl-2/fibroleukin in the donor modulates immunologic response and acute vascular rejection in cardiac xenografts. / Circulation. 2005;112:248-56. CrossRef
  
• 作者单位：Xiuli Dong (1)
  Xiaohua Ye (2)
  Xiangrong Chen (1)
  Tanzhou Chen (1)
  Saili Xie (1)
  Qinfan Li (1)
  Xiaoxiao Lin (1)
  Zhiming Huang (1)
  
  1. Department of Gastroenterology and Hepatology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, 32500, China
  2. Department of Gastroenterology, Jinhua Municipal Central Hospital, Jinhua Hospital of Zhejiang University, Jinhua, 321000, China
  
• ISSN：1573-2568

文摘

Background Fibrinogen-like protein 2 (FGL2), a new member of the fibrinogen-like family, has recently been identified as a novel immunosuppressive molecule. Aim The purpose of this work was to investigate intestinal and peripheral expression of FGL2 in patients with inflammatory bowel disease (IBD), mainly ulcerative colitis (UC) and Crohn’s disease (CD). Methods FGL2 expression in mucosal biopsies from three groups (UC group (n?=?61), CD group (n?=?54), and controls group (n?=?35)) was detected by immunohistochemistry. Concentrations of FGL2 in plasma from 50 UC patients, 45 CD patients, and 30 controls were analyzed by enzyme-linked immunosorbent assay. Western blot of FGL2 protein and real-time fluorescent quantitative PCR of FGL2 mRNA expression by peripheral mononuclear cells was performed. Correlations of FGL2 expression with disease type, activity, and location, and with measured laboratory data, including C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR), were examined. Results Intestinal and peripheral FGL2 protein data showed that FGL2 expression was significantly up-regulated in both UC and CD patients compared with controls (P?<?0.001). Expression of FGL2 was higher in UC and CD patients with active disease than in those with inactive disease (P?<?0.001). Moreover, FGL2 mRNA expression was significantly higher in patients with active disease than in those with inactive disease (P?<?0.050). Expression of FGL2 protein was correlated with disease activity indices, CRP levels, and ESR levels. Conclusion Expression of FGL2 was up-regulated in IBD patients with active disease. Measurement of FGL2 may be used as a helpful biomarker for understanding immunopathogenesis and for assessment of IBD.